These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16043754)

  • 1. Clinical significance of urinary liver-type fatty acid-binding protein in patients with diabetic nephropathy.
    Suzuki K; Babazono T; Murata H; Iwamoto Y
    Diabetes Care; 2005 Aug; 28(8):2038-9. PubMed ID: 16043754
    [No Abstract]   [Full Text] [Related]  

  • 2. Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes.
    von Eynatten M; Baumann M; Heemann U; Zdunek D; Hess G; Nawroth PP; Bierhaus A; Humpert PM
    Eur J Clin Invest; 2010 Feb; 40(2):95-102. PubMed ID: 19912308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.
    Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
    Diabetes Care; 2005 Nov; 28(11):2728-32. PubMed ID: 16249547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure.
    Nakamura T; Sugaya T; Koide H
    Diabetologia; 2007 Feb; 50(2):490-2. PubMed ID: 17171364
    [No Abstract]   [Full Text] [Related]  

  • 5. Urinary liver-type fatty acid-binding protein is a predictor of mortality in individuals with type 2 diabetes.
    Hamasaki H
    Diabet Med; 2021 Jun; 38(6):e14527. PubMed ID: 33474764
    [No Abstract]   [Full Text] [Related]  

  • 6. Adipocytokine zinc α2 glycoprotein (ZAG) as a novel urinary biomarker for normo-albuminuric diabetic nephropathy.
    Lim SC; Liying DQ; Toy WC; Wong M; Yeoh LY; Tan C; Lau D; Tan C; Subramaniam T; Sum CF
    Diabet Med; 2012 Jul; 29(7):945-9. PubMed ID: 22211921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of serum and urinary transforming growth factor-beta levels as markers of diabetic nephropathy.
    Mogyorósi A; Kapoor A; Isono M; Kapoor S; Sharma K; Ziyadeh FN
    Nephron; 2000 Oct; 86(2):234-5. PubMed ID: 11015017
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients.
    Kim SS; Song SH; Kim IJ; Yang JY; Lee JG; Kwak IS; Kim YK
    Diabetes Res Clin Pract; 2012 Aug; 97(2):251-7. PubMed ID: 22440044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycopatterns of Urinary Protein as New Potential Diagnosis Indicators for Diabetic Nephropathy.
    Zhu H; Liu M; Yu H; Liu X; Zhong Y; Shu J; Fu X; Cai G; Chen X; Geng W; Yang X; Wu M; Li Z; Zhang D
    J Diabetes Res; 2017; 2017():5728087. PubMed ID: 28401167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalbuminuric proteinuria as a biomarker for tubular damage in early development of nephropathy with type 2 diabetic patients.
    Kim SS; Song SH; Kim IJ; Kim WJ; Jeon YK; Kim BH; Kwak IS; Lee EK; Kim YK
    Diabetes Metab Res Rev; 2014 Nov; 30(8):736-41. PubMed ID: 24687388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of urinary biomarkers as a diagnostic tool for early diabetic nephropathy in patients with type 2 diabetes mellitus.
    Vijay S; Hamide A; Senthilkumar GP; Mehalingam V
    Diabetes Metab Syndr; 2018 Sep; 12(5):649-652. PubMed ID: 29673928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of increased serum cytokeratin 19 fragment levels in patients with diabetic nephropathy as a model of chronic renal failure.
    Kashiwabara K; Kishi K; Nakamura H; Yagyu H; Kobayashi K; Watanabe O; Matsuoka T
    Intern Med; 1998 Nov; 37(11):917-21. PubMed ID: 9868951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy.
    Nakamura T; Fujiwara N; Sugaya T; Ueda Y; Koide H
    Metabolism; 2009 Aug; 58(8):1185-90. PubMed ID: 19481229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cigarette smoking affects urinary liver-type fatty acid-binding protein concentration in patients with early diabetic nephropathy.
    Nakamura T; Sugaya T; Koide H
    Diabetes Care; 2006 Jul; 29(7):1717. PubMed ID: 16801619
    [No Abstract]   [Full Text] [Related]  

  • 15. Urinary afamin levels are associated with the progression of diabetic nephropathy.
    Kaburagi Y; Takahashi E; Kajio H; Yamashita S; Yamamoto-Honda R; Shiga T; Okumura A; Goto A; Fukazawa Y; Seki N; Tobe K; Matsumoto M; Noda M; Unoki-Kubota H
    Diabetes Res Clin Pract; 2019 Jan; 147():37-46. PubMed ID: 29522788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary monocyte chemoattractant protein-1 and vitamin D-binding protein as biomarkers for early detection of diabetic nephropathy in type 2 diabetes mellitus.
    Shoukry A; Bdeer Sel-A; El-Sokkary RH
    Mol Cell Biochem; 2015 Oct; 408(1-2):25-35. PubMed ID: 26104579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of renal function on serum and urinary heart fatty acid-binding protein levels.
    Nayashida N; Chihara S; Tayama E; Akasu K; Kai E; Kawara T; Aoyagi S
    J Cardiovasc Surg (Torino); 2001 Dec; 42(6):735-40. PubMed ID: 11698938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary platelet-derived growth factor-BB as an early marker of nephropathy in patients with type 2 diabetes: an Egyptian study.
    Bessa SS; Hussein TA; Morad MA; Amer AM
    Ren Fail; 2012; 34(6):670-5. PubMed ID: 22486214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy.
    Sasaki H; Kamijo-Ikemori A; Sugaya T; Yamashita K; Yokoyama T; Koike J; Sato T; Yasuda T; Kimura K
    Nephron Clin Pract; 2009; 112(3):c148-56. PubMed ID: 19390215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cigarette smoking on urinary podocyte excretion in early diabetic nephropathy.
    Nakamura T; Kawagoe Y; Koide H
    Diabetes Care; 2003 Apr; 26(4):1324-5. PubMed ID: 12663629
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.